SCHEMBL1500686

SCHEMBL1500686

CCOC(=O)Cc1cc(F)cc(Br)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.40
ALDH1A1 P00352 5/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CYP4Z1 Q86W10 1/20 0.38
GPR35 Q9HC97 1/20 0.38
CYP1A2 P05177 3/20 0.37
CYP2C19 P33261 3/20 0.37
GAA P10253 1/20 0.37
THRB P10828 1/20 0.37
TRPA1 O75762 1/20 0.37
MAPT P10636 3/20 0.37
LMNA P02545 3/20 0.37
NPSR1 Q6W5P4 3/20 0.37
CYP2C9 P11712 2/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
S1PR4 O95977 1/20 0.36
S1PR1 P21453 1/20 0.36
MAPK1 P28482 1/20 0.36
JAK2 O60674 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30739013 1.00 MAOB (0.40) MAOBALDH1A1SMN1; SMN2CYP4Z1GPR35
SCHEMBL24843182 0.88 SMN1; SMN2 (0.44) ALDH1A1SMN1; SMN2CYP4Z1GPR35CYP1A2
SCHEMBL2381215 0.88 MAOB (0.44) MAOBALDH1A1SMN1; SMN2CYP4Z1CYP1A2
SCHEMBL1559919 0.83 HSP90AB1 (0.53) ALDH1A1SMN1; SMN2GAAMAPTLMNA
SCHEMBL136475 0.82 HSP90AB1 (0.51) MAOBALDH1A1SMN1; SMN2CYP4Z1CYP1A2
SCHEMBL134983 0.81 MAPT (0.46) MAOBSMN1; SMN2CYP4Z1GPR35GAA
SCHEMBL20346364 0.80 NOTUM (0.50) ALDH1A1SMN1; SMN2GPR35CYP1A2CYP2C19
SCHEMBL18524392 0.79 SMN1; SMN2 (0.46) ALDH1A1SMN1; SMN2CYP1A2CYP2C19GAA
SCHEMBL15378035 0.79 MTNR1A (0.45) ALDH1A1MEN1KMT2A
SCHEMBL3371167 0.78 AKR1B1 (0.39) THRBMEN1KMT2AMAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4653436-A1 HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF GUANGZHOU YUFAN NANTU BIOTECHNOLOGIES CO., LTD (CN) 2025-11-26 EP disclosed
WO-2024153240-A1 HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF 珠海宇繁生物科技有限责任公司 2024-07-25 WO disclosed
US-20240109891-A1 NOVEL SUBSTITUTED TRICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2024-04-04 US disclosed
CN-117561258-A Novel substituted tricyclic aza heterocycles as SOS1 inhibitors 唯久生物技术(苏州)有限公司 2024-02-13 CN disclosed
WO-2022187236-A1 NOVEL SUBSTITUTED TRICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2022-09-09 WO disclosed
EP-2794563-B1 HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2017-02-22 EP disclosed
US-7906503-B2 Substituted 3-alkyl and 3-alkenyl azetidine derivatives MERCK SHARP & DOHME CORP. (US) 2011-03-15 US disclosed
US-7906652-B2 Heterocycle-substituted 3-alkyl azetidine derivatives MERCK SHARP & DOHME CORP. (US) 2011-03-15 US disclosed
US-20090069284-A1 Substituted 3-alkyl and 3-alkenyl azetidine derivatives MERCK SHARP & DOHME CORP. 2009-03-12 US disclosed
CN-101365694-A Heterocycle-substituted 3-alkyl azetidine derivatives MERCK & CO INC (US) 2009-02-11 CN disclosed
US-7485732-B2 Substituted 3-alkyl and 3-alkenyl azetidine derivatives MERCK & CO., INC. (US) 2009-02-03 US disclosed
EP-1960392-A2 HETEROCYCLE-SUBSTITUTED 3-ALKYL AZETIDINE DERIVATIVES Merck & Co., Inc. (US) 2008-08-27 EP disclosed
EP-1954692-A1 HETEROCYCLE-SUBSTITUTED 3-ALKYL AZETIDINE DERIVATIVES Merck and Co., Inc. (US) 2008-08-13 EP disclosed
WO-2007064566-A2 HETEROCYCLE-SUBSTITUTED 3-ALKYL AZETIDINE DERIVATIVES MERCK & CO., INC. (US) 2007-06-07 WO disclosed
WO-2007062193-A1 HETEROCYCLE-SUBSTITUTED 3-ALKYL AZETIDINE DERIVATIVES MERCK & CO., INC. (US) 2007-05-31 WO disclosed
US-20070123505-A1 Heterocycle-substituted 3-alkyl azetidine derivatives MERCK SHARP & DOHME CORP. 2007-05-31 US disclosed
US-20060293299-A1 Substituted 3-alkyl and 3-alkenyl azetidine derivatives MERCK SHARP & DOHME CORP. 2006-12-28 US disclosed
CN-1802351-A Substituted 3-alkyl and 3-alkenyl azetidine derivatives MERCK & CO INC (US) 2006-07-12 CN disclosed
EP-1636181-A1 SUBSTITUTED 3-ALKYL AND 3-ALKENYL AZETIDINE DERIVATIVES Merck & Co., Inc. (US) 2006-03-22 EP disclosed
WO-2005000809-A1 SUBSTITUTED 3-ALKYL AND 3-ALKENYL AZETIDINE DERIVATIVES MERCK & CO., INC. (US) 2005-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123505-A1 Heterocycle-substituted 3-alkyl azetidine derivatives CNR1, CNR2, FAAH MAOB 583/4885ALDH1A1 2197/4885SMN1; SMN2 418/4885
US-20240109891-A1 NOVEL SUBSTITUTED TRICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS SOS1, SOS2, KSR1 MAOB 3765/4885ALDH1A1 4112/4885SMN1; SMN2 1778/4885
US-20090069284-A1 Substituted 3-alkyl and 3-alkenyl azetidine derivatives CNR1, CNR2, MAG MAOB 778/4885ALDH1A1 2399/4885SMN1; SMN2 460/4885
US-20060293299-A1 Substituted 3-alkyl and 3-alkenyl azetidine derivatives CNR1, CNR2, MAG MAOB 778/4885ALDH1A1 2399/4885SMN1; SMN2 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.